AMH and meningioma: Although the vast majority of meningiomas are not malignant, identifying biomarkers that can predict their recurrence still holds clinical value, and lnc-GOLGA6A-1, ISLR2, and AMH demonstrated high prognostic potential for predicting meningioma recurrence, with lnc-GOLGA6A-1 being the most prominent [89].